当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated
药品名称
ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated
承诺描述
Conduct “A phase 3, multi-center, open label study to investigate safety and immunogenicity of ADYNOVATE in previously untreated patients(PUPs)” [clinical study 261203]. This study will evaluate on-demand treatment andcontrol of bleeding episodes in the setting of routine prophylaxis to reduce the frequencyof bleeding episodes, as well as the perioperative management of bleeding.